We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ARTO:EURONEXT PARISSociete Industrielle & Financiere de l'Artois SA Analysis

Data as of 2026-06-10 - not real-time

€9,100.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock trades at 9,100 €, comfortably above the 20‑day (9,085 €) and 50‑day (9,060 €) moving averages and the 200‑day level (8,838 €), indicating short‑term price momentum. Volume is increasing and the RSI sits near the neutral 52 mark, while the MACD histogram is negative, signaling a bearish divergence that could temper the bullish trend. Beta is low at 0.32 and 30‑day volatility is moderate at 16 %, suggesting limited price swings relative to the market.
Fundamentally, the company appears severely overvalued with a trailing P/E of 294 versus an industry average of 35, and revenue has fallen 15 % year‑over‑year. Operating and EBITDA margins are negative, cash‑flow generation is weak, and the dividend payout ratio exceeds 200 %, raising serious doubts about dividend sustainability. The balance sheet shows a high debt‑to‑equity of 3.1, while ROE is near zero, highlighting financial fragility despite a modest market cap.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above key moving averages supports near‑term momentum
  • Increasing volume indicates trader interest
  • Bearish MACD histogram warns of potential pullback

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Trailing P/E of 294 far exceeds industry norm
  • Negative earnings, cash flow and a 15 % revenue decline
  • Dividend payout ratio over 200 % is unsustainable

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio (3.1) stresses the balance sheet
  • Near‑zero ROE and negative ROA indicate poor capital efficiency
  • Low beta and moderate volatility provide limited upside in a turnaround

Key Metrics & Analysis

Financial Health

Revenue Growth-15.10%
Profit Margin6.09%
P/E Ratio294.1
ROE0.04%
ROA-0.35%
Debt/Equity3.10
P/B Ratio1.1
Op. Cash Flow€-14430000
Free Cash Flow€-2912125
Industry P/E35.2

Technical Analysis

TrendBullish
RSI52.0
Support€9,000.00
Resistance€9,200.00
MA 20€9,085.00
MA 50€9,060.00
MA 200€8,838.00
MACDBearish
VolumeIncreasing
Fear & Greed Index81.75

Valuation

GradeOvervalued
TypeValue
Dividend Yield0.75%

Risk Assessment

Beta0.32
Volatility16.20%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.